Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2026 17:29 ET | Source: Nanobiotix S.A.

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based...
May 04, 2026 16:30 ET | Source: Opus Genetics, Inc.

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
May 04, 2026 16:30 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter...
May 04, 2026 16:30 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the...
May 04, 2026 16:15 ET | Source: AnaptysBio, Inc.

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today...
May 04, 2026 16:05 ET | Source: Capricor Therapeutics

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing...
May 04, 2026 16:05 ET | Source: Kyntra Bio

Kyntra Bio to Report First Quarter 2026 Financial Results

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct...
May 04, 2026 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported...
May 04, 2026 16:05 ET | Source: Aktis Oncology Inc.

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid...
May 04, 2026 16:01 ET | Source: Ocugen

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...